After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.
The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.
The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
Veracyte said that the draft policy is open to a 45-day comment period and could potentially go into effect in early 2019.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
Veracyte anticipates that it can tap into the growing precision medicine market by leveraging its database of RNA sequencing data for thyroid and lung cancer.
The firm will use the proceeds for working capital, but said it may also acquire or invest in complementary technologies or businesses.
The firm beat analysts' consensus estimates on both the top and bottom lines, and it raised its 2018 annual revenue guidance.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.
A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.
An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.
In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.